J82 Xenograft Model Service for Bladder Cancer

The J82 Xenograft Model Service for Bladder Cancer provides a robust, clinically relevant preclinical platform for evaluating therapeutic efficacy against muscle-invasive urothelial carcinoma. At Alfa Cytology, we specialize in delivering high-fidelity J82 xenograft models tailored to your drug development pipeline, combining stringent quality control with customizable study designs to accelerate your preclinical research outcomes.

Overview of J82 Xenograft Model for Bladder Cancer

The J82 cell line (ATCC HTB-1) was originally established from a primary bladder tumor of a 58-year-old Caucasian male diagnosed with high-grade, muscle-invasive transitional cell carcinoma (Stage T3, Grade 3). As one of the most extensively characterized urothelial carcinoma models, J82 exhibits epithelial morphology, aneuploid karyotype, and harbors key oncogenic alterations including H-ras activation, homozygous PTEN deletion, RB1 splice mutation, and PIK3CA mutation. These molecular features closely mirror the genomic landscape of aggressive human bladder cancer, making J82 xenografts a cornerstone for preclinical pharmacology and translational oncology studies.

In xenograft applications, J82 cells demonstrate consistent tumorigenicity across immunodeficient mouse strains, forming subcutaneous tumors with predictable growth kinetics and histopathological features reminiscent of human muscle-invasive bladder cancer. The model supports both standard subcutaneous implantation and orthotopic bladder wall injection protocols, enabling researchers to evaluate compound efficacy, tumor penetration, and biomarker modulation in a physiologically relevant context. J82 xenografts have been successfully employed in studies targeting EGFR degradation, STAT3/BCL-xL axis inhibition, autophagy induction, and immune checkpoint modulation, underscoring its versatility across diverse therapeutic modalities.

Figure 1. Synergic anti-bladder cancer effects of NP-AAG in vitro. (Long, Q, et al., 2018)

Cell Line Information: J82

The following table summarizes the essential characteristics and culture requirements of the J82 cell line for xenograft model development:

Our Services

Alfa Cytology leverages decades of collective expertise in preclinical oncology to deliver J82 xenograft models with unparalleled consistency and scientific rigor. Our end-to-end service encompasses cell line authentication, pathogen screening, tumor implantation, longitudinal monitoring, and comprehensive endpoint analysis---including tumor volume measurements, body weight tracking, histopathology, immunohistochemistry, and biomarker quantification. Whether you require standard subcutaneous models, orthotopic bladder implantations, or luciferase-labeled J82 derivatives for bioluminescence imaging, our team designs each study to meet your specific therapeutic hypothesis and regulatory milestones, ensuring reproducible data that stands up to peer review and IND-enabling scrutiny.

Workflow of J82 Xenograft Model Construction

The construction of J82 xenograft models at Alfa Cytology follows a standardized yet flexible workflow designed to maximize tumor take rates, minimize inter-animal variability, and generate pharmacologically relevant data. The process begins with rigorous cell line quality assurance and concludes with comprehensive endpoint analysis, ensuring every study meets the highest preclinical standards.

1. Cell Line Preparation and Authentication --- J82 cells are revived from authenticated master stocks (ATCC HTB-1) and expanded under strict aseptic conditions. Short tandem repeat (STR) profiling confirms cell identity, while mycoplasma testing and pathogen screening ensure culture purity. Cells are harvested during the logarithmic growth phase to maximize viability and tumorigenic potential.
2. Cell Suspension Formulation --- Harvested cells are washed with sterile PBS, counted using a hemocytometer or automated cell counter, and resuspended at the desired concentration (typically 1x10^6 to 5x10^6 cells per 100--200 uL) in serum-free medium or PBS. For enhanced tumor engraftment, cells may be mixed 1:1 with Matrigel or similar extracellular matrix scaffold prior to injection.
3. Animal Preparation and Ethical Review --- Immunodeficient mice (commonly BALB/c nude or NOD-SCID, 4--6 weeks old, female) are acclimatized for 5--7 days under specific pathogen-free (SPF) conditions. All procedures are conducted under approved IACUC protocols with continuous veterinary oversight, ensuring humane handling and compliance with international animal welfare guidelines.
4. Tumor Cell Implantation --- For subcutaneous models, the J82 cell suspension is injected into the right flank using a sterile 25--27G needle. For orthotopic models, cells are instilled into the bladder wall via intravesical or surgical injection under anesthesia. Tumor take rates for J82 subcutaneous xenografts typically exceed 90%, with palpable tumors appearing within 7--14 days post-implantation.
5. Tumor Monitoring and Randomization --- Tumor growth is monitored twice weekly by caliper measurements (length x width) and volume calculation using the formula V = 0.5 x L x W^2. Mice are randomized into treatment groups when tumors reach 70--150 mm^3, ensuring balanced baseline tumor volumes across cohorts. Body weights and clinical observations are recorded concurrently to assess general health.
6. Treatment Administration and Study Execution --- Test compounds, vehicle controls, or reference standards are administered via the designated route (oral gavage, intraperitoneal, intravenous, or intravesical) according to the study protocol. Dosing schedules are customized to match compound pharmacokinetics and therapeutic windows, with treatment durations typically ranging from 14 to 28 days.
7. Endpoint Analysis and Data Reporting --- At study termination, tumors are excised, weighed, and processed for downstream analyses including H&E staining, IHC (Ki-67, CD31, TUNEL), Western blot, qPCR, and flow cytometry. Tumor growth inhibition (TGI), tumor regression rates, and pharmacodynamic biomarkers are calculated and reported with full statistical analysis.

Figure 2. J82 xenograft model construction workflow.

Case Study-J82 Xenograft Model Development

In a representative preclinical engagement, Alfa Cytology established subcutaneous J82 xenografts in BALB/c nude mice to evaluate a novel therapeutic candidate targeting the EGFR/STAT3 signaling axis. Following successful tumor engraftment and randomization at ~100 mm^3, animals received the investigational compound or vehicle control over a 21-day treatment period. The study demonstrated dose-dependent tumor growth inhibition, with the high-dose cohort achieving statistically significant reduction in tumor burden compared to control. Pharmacodynamic analyses confirmed target engagement through decreased p-STAT3 and downstream BCL-xL expression in treated tumors, while maintaining acceptable body weight profiles. Histopathological examination revealed increased apoptotic indices (TUNEL-positive cells) and reduced Ki-67 proliferation markers in responder tumors. Complete dataset, statistical parameters, and customized analysis packages are available upon formal inquiry.

Why Choose Alfa Cytology?

Alfa Cytology distinguishes itself as a premier preclinical CRO through unwavering commitment to scientific excellence, operational transparency, and client-centric flexibility. Our J82 xenograft service is built on validated methodologies, authenticated cell stocks, and rigorous quality assurance protocols that ensure reproducible, audit-ready data for your IND submission or publication needs.

• Authenticated J82 master stocks with quarterly STR verification and comprehensive mycoplasma/pathogen screening.
• Customizable study designs encompassing subcutaneous, orthotopic, and bioluminescence-labeled J82 models with flexible dosing regimens.
• Real-time tumor monitoring via digital caliper tracking and optional in vivo imaging (IVIS) for longitudinal bioluminescence quantification.
• Comprehensive endpoint portfolio including histopathology, immunohistochemistry, Western blot, qPCR, flow cytometry, and plasma/urine biomarker analysis.
• Dedicated project management with weekly progress updates, raw data transparency, and rapid turnaround from study initiation to final report.
• Competitive pricing structures without compromising on animal welfare standards, regulatory compliance, or data integrity.

Contact Us

Ready to advance your bladder cancer therapeutic pipeline with a validated J82 xenograft model? Contact us today to discuss your study objectives, timeline, and budget. Our scientific team is prepared to design a customized preclinical strategy that aligns with your regulatory milestones and accelerates your path from bench to bedside. Please reach out to us today via our inquiry form or email to learn more about our J82 Xenograft Model services.

For research use only. Not intended for any clinical use.